We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.42B
1-Year Est. Return 34.72%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$717M
AUM Growth
+$114M
Cap. Flow
+$68.8M
Cap. Flow %
9.59%
Top 10 Hldgs %
100%
Holding
11
New
4
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AXON
Axon Enterprise
AXON
+$9.39M
2
LCTX icon
Lineage Cell Therapeutics
LCTX
+$6.72M
3
AST
Asterias Biotherapeutics Inc. Series A
AST
+$4.03M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$24.1M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.32%
2 Healthcare 36.42%
3 Industrials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNST icon
1
Monster Beverage
MNST
$94.3B
$304M 42.32%
9,594,816
– –
STAA icon
2
STAAR Surgical
STAA
$1.21B
$168M 23.45%
10,855,179
– –
LCTX icon
3
Lineage Cell Therapeutics
LCTX
$269M
$64.4M 8.98%
34,257,494
+3,077,307
+10% +$6.72M
IWM icon
4
iShares Russell 2000 ETF
IWM
$79.8B
$64M 8.93%
420,000
– –
BA icon
5
PUT
Boeing
BA
$171B
$32.4M 4.52%
+110,000
New +$29.8M
MNST icon
6
PUT
Monster Beverage
MNST
$94.3B
$31.6M 4.41%
+1,000,000
New +$30M
IMDX
7
Insight Molecular Diagnostics
IMDX
$150M
$16.7M 2.33%
179,834
– –
DAL icon
8
PUT
Delta Air Lines
DAL
$57.5B
$14M 1.95%
+250,000
New +$13.1M
AST
9
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$11.9M 1.66%
5,292,156
+1,592,308
+43% +$4.03M
AXON
10
Axon Enterprise
AXON
$42.5B
$10.4M 1.44%
+391,092
New +$9.39M
MNK
11
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-644,822
Closed -$24.1M

Similar funds

PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.41B AUM 18.71% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
PPC
Park Presidio Capital San Francisco, California $1.43B AUM 21.33% 1-Year Est. Return

Broadwood Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Broadwood Capital held 11 positions worth $717M, up 19% from $604M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital deployed $68.8M of net new capital in Q4 2017, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Axon Enterprise: 391,092 shares worth $10.4M.

By sector, the portfolio is most concentrated in Consumer Staples at 42% of assets, down from 44% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $24.1M sold.

  • Broadwood Capital's largest Q4 2017 buy was Axon Enterprise: 391,092 shares worth $10.4M.
  • Broadwood Capital added most to Lineage Cell Therapeutics in Q4 2017, an estimated $6.72M increase.
  • Broadwood Capital fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $24.1M.
  • Broadwood Capital's ten largest holdings make up 100% of its $717M portfolio in Q4 2017.
  • Broadwood Capital opened 4 new positions and closed 1 in Q4 2017.
  • Broadwood Capital's portfolio value rose 19% quarter-over-quarter to $717M.

Based on Broadwood Capital's 13F filing for Q4 2017, filed 14 Feb 2018.